Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| 60 Degrees Pharmaceuticals Inc | SXTPW | NASDAQ | Equity Warrant |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.037255 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.037255 |
| Trades | Volume | Avg Volume |
|---|---|---|
| 0 | 0 | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | 0.037255 | USD |
60 Degrees Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 216.08k | 5.80M | - | 254k | -3.77M | -0.65 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
News 60 Degrees Pharmaceuticals
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
SXTPW Historical
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Its lead product, ARAKODA (tafenoquine), is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older. The Company's pipeline under development covers development programs for COVID-19, fungal, tick-borne, and other viral diseases; new products that contain the Arakoda regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. The ARAKODA regimen of tafenoquine is in Phase II study data in patients with mild-moderate COVID-19 disease. It is also planning a clinical study to assess the utility of ARAKODA as a treatment for human babesiosis. The Company is also developing Celgosivir for the treatment of COVID-19, respiratory syncytial virus (RSV), and dengue. |
